Tag Archives: vemurafenib

June, 2018

5 June
Array Announces Additional Median Overall Survival Results of Encorafenib and Binimetinib in Patients with Braf-Mutant Advanced Melanoma

BOULDER, Colo., June 4, 2018 /PRNewswire/ — Array BioPharma Inc. (NASDAQ: ARRY) today announced updated results from the Phase 3 COLUMBUS trial in BRAF-mutant advanced melanoma. The results showed median overall survival (mOS) was 33.6 months for patients treated with the combination of encorafenib and binimetinib compared to 16.9 months for patients treated with vemurafenib as …
Share

6 November
FDA Approves Genentech’s Zelboraf for Treatment of Patients with a Rare Blood Cancer

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Zelboraf® (vemurafenib) for Erdheim-Chester disease (ECD) with BRAF V600 mutation. ECD is a rare, serious blood disease characterized by the abnormal multiplication of …
Share

7 March
Blood Test May Give Early Warning of Skin Cancer Relapse

A blood test may be able to sound early warning bells that patients with advanced melanoma skin cancer are relapsing, according to a study published in the journal Cancer Discovery today. Scientists from the Cancer Research UK Manchester Institute studied the DNA shed by tumours into the bloodstream – called circulating tumour DNA …
Share